Omixon Holotype HLA™ Update Presentation This Week in Cambridge at BSHI


Join us for a 20 minute presentation at BSHI in Cambridge.

Event:   Holotype HLA™ Update Presentation
Room:  Glover Room (Gillespie Conference Centre)
Date:     September 9, 2015, Wednesday
Time:    12:45pm-1:05pm CET


  • Introducing Holotype HLA™
  • Early Access Program Update


Tim Hague (CEO, Omixon)
A passionate biotechnology executive combining a science education with a strong IT background. Tim joined Omixon as a Software Architect before swiftly taking on the role of CTO, a position he held for more than 3 years. In 2013 he became Omixon’s CEO, adding world-wide responsibility for sales, marketing, HR and finances to his existing leadership of research and development. Before joining Omixon, he accumulated 15 years of software engineering and design expertise as Architect/Design Lead at Lufthansa Systems, Technical Consultant at iE and Technical Team Leader at IBM, among others. Tim received a BSc in Genetics from Nottingham University and an MSc in Information Systems Design from the University of Westminster.

Marcello Scala (Sales Manager, EMEA & Asia, Omixon)
Marcello is a young and ambitious Sales & Marketing professional, highly passionate about genetics. After living in Shanghai, China, as Business Development Manager for Shanghai GenePharma (an RNAi company), he spent three years within the HLA field as Marketing and Sales Manager for ROSE GenTec Ltd. For Omixon he is responsible for sales to direct customers, within the EMEA and Asian territories. Marcello received a BSc in Medical Biotechnology from the University of Naples “Federico II”, and an MSc in Genetics, with full scholarship from the B.I.O.G.E.M. research centre University of Sannio. He is also currently taking part of the Executive MBA program at the University of West England.